Eli Lilly shares hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares rose 4.1% to $1,126.80. The company’s market capitalization recently moved back above $1 trillion,

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Participants in Eli Lilly’s TRIUMPH-1 trial lost an average of roughly 85 pounds on the highest dose of retatrutide, an experimental obesity pill that targets three metabolic hormones at once. No oral medication has ever come close to that figure in a late-stage study.